Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Earnings Release 2024

Feb 14, 2025

3535_rns_2025-02-14_43467d99-0f4f-4608-8ca4-a6a7791b2cb0.html

Earnings Release

Open in viewer

Opens in your device viewer

Specification regarding expected results for 2024

Specification regarding expected results for 2024

14.2.2025 13:57:58 CET | Aqua Bio Technology ASA | Additional regulated

information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA ('ABT' or 'the Company') announced on February 12, 2025,

that the negative result for 2024 is primarily due to significant impairments of

goodwill related to the bankruptcy of its subsidiary, Skinteam Norge AS, as well

as operating losses in two of the Group's subsidiaries.

ABT emphasizes that the majority of the operating losses in two subsidiaries in

2024 are due to significant and extraordinary impairments.

- The impairments position the group better to deliver shareholder value in the

future,' says Fredrik William Henriksen.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section

of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Fredrik Henriksen, CEO, Aqua Bio Technology ASA, +47 90 02 00 78,

[email protected]

* Geir Udnæs, CFO, Aqua Bio Technology ASA, +47 91 36 18 93,

[email protected]

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology ASA (ABT) is a distribution group in skincare and nonfood.

The group has distribution towards B2C, B2B, B2B2, and freight, customs, and

logistics services. The group also develops sustainable biotechnology for use in

skincare products. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/18423779/5634/Download%20announce

ment%20as%20PDF.pdf